Rituximab and ABVD for Hodgkin's Patients

Phase 2 Completed 85 enrolled M.D. Anderson Cancer Center Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.

Timeline

Start: 2001-03
Primary completion: 2012-03
Completion: 2012-03

Publications

Results Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4123-8. doi: 10.1182/blood-2012-01-405456. Epub 2012 Feb 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bleomycin	Unknown	10 unknown	Intravenous
Subject	Dacarbazine	Small molecule	375 mg/m2	—
Subject	Doxorubicin	Other / unclassified	25 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vinblastine	Small molecule	6 mg/m2	Intravenous

Rituximab and ABVD for Hodgkin's Patients

Summary

Timeline

Publications

Drugs

Indications